General Psychiatry - Articles - Page 46

Learning Objectives, Living With Mental Illness, TCPR, March 2022

March 4, 2022

After reading these articles, you should be able to…

CME Post-Test - Living With Mental Illness, TCPR, March 2022

March 4, 2022

By successfully completing the test you will be awarded a certificate for 1 CME credit.

EXPERT Q&A

Raising the Bar in Schizophrenia Treatment

January 31, 2022

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH Professor of Psychiatry at the Medical College of Georgia, Augusta, and President of the Georgia Psychiatric Physicians Association. Dr. Miller receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute.

Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia.

An Off-Label Guide to Gabapentin

January 31, 2022

Rajesh R. Tampi, MD, MS, DFAPA. and Chris Aiken, MD.

Rajesh R. Tampi, MD, MS, DFAPA. Professor of Medicine, Case Western Reserve University. Chairman, Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, and Chief of Geriatric Psychiatry, Cleveland Clinic. Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Off-label gabapentin (Neurontin) got a bad rep when it missed the mark in bipolar disorder, but there may be something worth salvaging in this drug. Here, we weigh its pros and cons for anxiety, substance use disorders, sleep, pain, and hot flashes, and compare it to its underutilized cousin, pregabalin (Lyrica).

MDMA-Assisted Therapy for Severe PTSD

January 31, 2022

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.

Lumateperone in Bipolar Depression

January 31, 2022

John C. Raiss, MD.

John C. Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.

RESEARCH UPDATE

A Novel Treatment for Methamphetamine Use Disorder

January 31, 2022

David A. Moltz, MD.

David A. Moltz, MD. Dr. Moltz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring.

Lybalvi: The Diet Olanzapine

January 31, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?